Ownership and insider activity for BridgeBio Oncology Therapeutics Inc. (BBOT): insider transactions, US Senate and House trading disclosures and shares outstanding. Track how corporate insiders and politicians are trading the stock.
BridgeBio Oncology Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of small-molecule therapeutics for the treatment of renin-angiotensin system and phosphoinositide 3-kinase malignancies in the United States.
Price
| Price | $4.76 |
| Market Cap | $381M |
| Exchange | NASDAQ |
| Country | US |
Recent Insider Transactions
| Date | Insider | Type | Shares | Value |
|---|---|---|---|---|
| 2026-09-10 | Cobo Marc | A-Award | 43,700 | $241K |
| 2026-09-10 | Cobo Marc | A-Award | 9,038 | |
| 2026-09-10 | Cobo Marc | F-InKind | 203 | $1K |
| 2026-07-01 | Cobo Marc | F-InKind | 125 | $975 |
| 2026-07-01 | Elmelech Idan | F-InKind | 343 | $3K |
| 2026-07-01 | Ben Yong | F-InKind | 1,047 | $8K |
| 2026-07-01 | Beltran Pedro | F-InKind | 1,047 | $8K |
| 2026-07-01 | Chen Bihua | J-Other | 130,865 | |
| 2026-07-01 | Chen Bihua | J-Other | 1,704,862 | |
| 2026-07-01 | Chen Bihua | J-Other | 2,692,459 |
Balance Sheet (10y)
| Year | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 0 | 0 | 0 | $1.7M | $373.7M |
| Short-term Investments | 0 | 0 | 0 | 0 | $51.8M |
| Receivables | 0 | 0 | 0 | 0 | $386000 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Total Current Assets | 0 | 0 | 0 | $1.9M | $425.5M |
| Property, Plant & Equipment | 0 | 0 | 0 | 0 | 0 |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 |
| Total Assets | $144281 | $144578 | $332894 | $194.4M | $448.4M |
| Accounts Payable | 0 | 0 | 0 | 0 | $1.4M |
| Short-term Debt | $36961 | $43106 | $70095 | 0 | 0 |
| Total Current Liabilities | $162638 | $166455 | $396463 | $187515 | $35.0M |
| Long-term Debt | 0 | 0 | 0 | 0 | $2.2M |
| Total Liabilities | $162638 | $166455 | $396463 | $5.7M | $37.3M |
| Retained Earnings | -$43357 | -$46877 | -$88569 | -$3.7M | -$356.6M |
| Total Equity | -$18357 | -$21877 | -$63569 | $188.7M | $411.1M |
| Total Debt | $36961 | $43106 | $70095 | 0 | $2.8M |
| Net Debt | $36961 | $43106 | $70095 | -$1.7M | -$422.7M |
| Working Capital | -$162638 | -$166455 | -$396463 | $1.8M | $390.4M |
Financial Health
| Debt / Equity | 0.01 |
| Current Ratio | 4.69 |
Profitability
| Return on Equity | -46.90% |
| Return on Invested Capital | -61.10% |
| Return on Assets | -48.34% |
| Gross Margin | 0.00% |
| Operating Margin | 0.00% |
| Net Margin | 0.00% |
Related companies: ANAB · KOD · MNMD · NRIX · OCS · PHAT · SEPN
Explore sector: Healthcare · Biotechnology
More sections of BBOT: Overview · Financials · Valuation · Statistics · Estimates · Technical · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks